Series: The T Files — Series 4: “Gels, Patches & the Skin Transfer Disaster"
Subtitle: The transdermal era promised to fix everything. Then men started accidentally hormoning their wives.
Post: 5 of 5
Tags: pharmacokinetics, testosterone delivery comparison, AndroGel vs injections, transdermal testosterone, physiological levels, 1990 WHO consensus, Fortesta, Testim, Vogelxo, Axiron, TRT outcomes
Word Count: ~1,150
In 1990, the WHO/NIH/FDA expert workshop on testosterone therapy issued a formal consensus statement. The goal of TRT, it said, was to achieve stable physiological serum testosterone levels. No currently available preparation consistently achieved this.
Twelve years later, in 2000, AndroGel arrived in the United States. It provided continuous serum testosterone absorption over 24 hours. Steady-state levels for most patients on 50 mg/day maintained troughs above 360 ng/dL and peaks below 875 ng/dL — well within the physiological range, without the dramatic supratherapeutic spikes of injections.
Had the field finally found its Goldilocks formulation? Not quite — but it was the closest anyone had come, and understanding why requires comparing all the major delivery systems against the same standard.
The Goldilocks Framework
The 1990 consensus goal is a useful benchmark: stable serum testosterone in the physiological range (400–700 ng/dL by most guidelines, with an acceptable window of roughly 300–1,000 ng/dL) maintained consistently throughout the dosing interval.
Against this standard, the major delivery systems perform as follows:
Testosterone enanthate or cypionate (every 2–4 weeks):
- Peak at 36–48 hours: >1,200 ng/dL — clearly supratherapeutic
- Trough at end of interval: <300 ng/dL — clearly subtherapeutic at longer intervals
- Assessment: Pharmacokinetically far from the goal; peaks and troughs both outside physiological range
Testosterone enanthate/cypionate (weekly, 75–100mg):
- Substantially reduced peak-trough variation compared to biweekly/monthly dosing
- Peaks more likely in the high physiological range rather than supratherapeutic
- Troughs maintained near the lower physiological limit
- Assessment: Meaningfully better, but still a sawtooth curve rather than a flat line; practical for many patients who self-inject
Androderm patch (4 mg/day nightly):
- Peak within the physiological range (765 ng/dL at ~8 hours)
- Continuous absorption over 24 hours mimicking circadian pattern
- Quick return to hypogonadal levels within 24 hours of removal (good reversibility; less ideal if skin reactions cause inconsistent use)
- 48% application site reaction rate
- Assessment: Pharmacokinetically excellent; tolerability disqualifying for a significant portion of patients
AndroGel 1% (50 mg/day):
- Peaks at 16–22 hours; continuous absorption throughout 24-hour period
- Steady-state Cmin ~360 ng/dL, Cmax ~875 ng/dL — both within physiological range
- Skin reaction rate dramatically lower than patch
- Requires hand washing, clothing coverage; Boxed Warning for secondary transfer
- Assessment: Closest to the 1990 goal; good tolerability with behavioral precautions required
AndroGel 1.62%, Testim, Vogelxo, Axiron, Fortesta:
- All share the same continuous absorption principle
- Subtle pharmacokinetic differences between products (Testim, for example, has a Cmax ~30% higher than AndroGel at equivalent doses; Fortesta peaks earlier at 2–4 hours; Axiron peaks at 2–4 hours via underarm application)
- Same Boxed Warning for secondary transfer applies to all
- Assessment: Slight variations in PK profile but broadly similar outcomes; product choice often driven by patient preference, application site, and dose flexibility
Why the Differences Between Gel Products Matter (A Little)
The various testosterone gels are not interchangeable in all circumstances. A direct pharmacokinetic comparison study found that Testim and AndroGel at equivalent 50 mg doses are not bioequivalent — Testim produces a mean Cmax of 480 ng/dL versus 368 ng/dL for AndroGel, and a mean AUC0-24 that is 30% higher. The FDA rates them as not therapeutically equivalent.
Fortesta’s earlier peak (2–4 hours after application) differs from AndroGel’s later peak (16–22 hours). For patients monitored by labs drawn at specific time points relative to application, the choice of product matters for accurate level interpretation.
Axiron’s underarm application site and roll-on applicator represent a practical difference in secondary exposure risk management. The applicator minimizes hand contact with testosterone solution; the underarm site is less likely to be casually contacted by children.
Vogelxo showed in a 406-subject comparison study that it produces less moment-to-moment fluctuation in 24-hour testosterone levels than the Androderm patch, while achieving better therapeutic-range coverage with appropriate dose titration.
None of these differences are dramatic. All of these products are approaching the same pharmacokinetic goal — continuous absorption, stable physiological levels — and all are achieving it reasonably well. The differences that matter most clinically are often practical: which site does the patient prefer, which dose increments fit their needs, what is their insurance coverage.
The Outcomes Case for Stable Levels
The pharmacokinetic argument for stable delivery matters beyond theoretical elegance. Clinical evidence suggests that the emotional and cognitive symptoms associated with injection therapy’s peak-trough cycling are real and are mediated by the hormone fluctuations themselves.
In comparative studies, patients switching from biweekly or monthly injections to daily transdermal therapy reported significant improvements in mood stability, energy consistency, and subjective wellbeing — even when mean serum testosterone levels were similar between formulations. The degree of fluctuation mattered, not just the average.
This is consistent with basic endocrinology: the body maintains homeostasis in part by adapting to stable hormone levels. Tissues that respond to testosterone — brain tissue, muscle tissue, the HPG axis itself — calibrate their sensitivity over time. Rapid oscillation between high and low levels is physiologically disruptive in ways that stable delivery at the same average is not.
The 1990 consensus was right: the goal was physiological stability, and the reason was not merely aesthetic. It was mechanistically important.
The Remaining Problem
So the transdermal era arrived, solved the pharmacokinetic problem, improved tolerability substantially (at least for gels versus patches), and brought TRT to something approaching the 1990 consensus goal. What still wasn’t solved?
Two things.
First, daily application. All transdermal products require daily administration. Patients must remember, every morning, to apply their testosterone. This is not a trivial burden for a lifetime therapy. Adherence data for daily gel therapy is better than for injections in some analyses, worse in others, and highly individual.
Second, secondary transfer. The Boxed Warning is not a footnote. It requires consistent behavioral compliance. For patients who live with small children, whose partners are pregnant, or who share close physical contact with others regularly, the management requirements are meaningful and the risk — even with compliance — is not zero.
The transdermal era’s answer to injections was real and clinically meaningful. It was also incomplete. The field was still looking for a delivery system that maintained stable, physiological levels without injection burden, without secondary transfer risk, and without daily application demands.
That search eventually pointed toward an entirely different mode of thinking about what “transdermal” could mean — specifically, whether spray-based systems that absorbed rapidly and completely could achieve the hormonal stability of gels while minimizing the surface residue that makes transfer possible.
That story belongs to later chapters of The T Files. For now, the transdermal era stands as a genuine advance that solved the pharmacokinetic rollercoaster — and introduced us, along the way, to Boxed Warnings, skin blistering rates, and the concept of a man who accidentally hormonates his partner by failing to wear a shirt.
Progress, by definition, is incremental.
Coming up in Series 5 — “The Heart Scare That Almost Killed TRT": By 2010, testosterone therapy had millions of users, a well-established pharmacological track record, and a growing body of prescribers. Then a small stopped trial published in JAMA — 209 men, five months, an elderly high-risk population — generated a headline that the field would spend thirteen years trying to answer properly: does testosterone therapy cause heart attacks? We examine the 2010 Basaria study, the flawed 2013 Vigen meta-analysis, the FDA warning that followed, and the 5,246-patient TRAVERSE trial that finally settled the question.
